AR100608A1 - Complejos de citomegalovirus y usos de los mismos - Google Patents

Complejos de citomegalovirus y usos de los mismos

Info

Publication number
AR100608A1
AR100608A1 ARP150101642A ARP150101642A AR100608A1 AR 100608 A1 AR100608 A1 AR 100608A1 AR P150101642 A ARP150101642 A AR P150101642A AR P150101642 A ARP150101642 A AR P150101642A AR 100608 A1 AR100608 A1 AR 100608A1
Authority
AR
Argentina
Prior art keywords
complexes
citomegalovirus
same
pentameric
proteins
Prior art date
Application number
ARP150101642A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR100608A1 publication Critical patent/AR100608A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona proteínas gL de citomegalovirus (CMV) modificadas y complejos que comprenden proteínas gL, en particular complejos pentaméricos que comprenden gH, gL, pUL128, pUL130, pUL131. La divulgación también proporciona procedimientos de purificación de complejos pentaméricos y de reducción de complejos diméricos contaminantes que consisten en gH y gL. También se proporcionan usos de complejos pentaméricos en composiciones inmunógenas y vacunas.
ARP150101642A 2014-05-27 2015-05-26 Complejos de citomegalovirus y usos de los mismos AR100608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14170137 2014-05-27

Publications (1)

Publication Number Publication Date
AR100608A1 true AR100608A1 (es) 2016-10-19

Family

ID=50884237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101642A AR100608A1 (es) 2014-05-27 2015-05-26 Complejos de citomegalovirus y usos de los mismos

Country Status (3)

Country Link
AR (1) AR100608A1 (es)
BE (1) BE1023213B1 (es)
WO (1) WO2015181142A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Also Published As

Publication number Publication date
BE1023213A1 (fr) 2016-12-21
BE1023213B1 (fr) 2016-12-21
WO2015181142A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
AR100608A1 (es) Complejos de citomegalovirus y usos de los mismos
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
JO3765B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18 (18hpv)
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
BR112017011215A2 (pt) partículas de distribuição de pró-flavorizante
MX2020005187A (es) Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.
DK3244917T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
MX2017002438A (es) Formulacion topica.
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
DK3570879T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MY181175A (en) Therapeutic hpv16 vaccines
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
MY191539A (en) Streptococcal vaccine
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
ZA202204981B (en) Synthetic chimeric poxviruses
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
UY36150A (es) Derivados de naftiridinadiona
EP3149471A4 (en) Improvements in using blood culture platforms for commercial sterility tests
BR112016022787A2 (pt) método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica

Legal Events

Date Code Title Description
FB Suspension of granting procedure